Radiation therapy utilization and outcomes for older women with breast cancer

Impact of molecular subtype and tumor grade

Waqar Haque, Denley Ming Kee Yuan, Vivek Verma, E. Brian Butler, Bin S. Teh, Lee Wiederhold, Sandra Hatch

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Radiation therapy (RT) utilization for elderly women with respect to human epidermal growth factor receptor 2 (HER2) receptor status has not been evaluated. Our purpose was to determine differences in RT utilization and breast cancer specific survival (BCSS) for elderly breast cancer patients with distinct molecular biomarkers. Methods The Surveillance, Epidemiology, and End Results database was queried for women ≥70 years of age diagnosed with T1N0M0 breast cancer between 2010 and 2013 receiving breast conservation. Chi-squared analysis was performed to determine the difference in RT utilization between groups. Multivariable logistic regression analysis was performed to determine predictors for RT use. Kaplan-Meier curves were created and the log-rank test done to compare differences in breast cancer specific survival (BCSS) between groups. Results A total of 12,312 patients met the inclusion criteria. Receipt of RT for patients with distinct tumor biomarkers was as follows: 55.7% for patients with Estrogen Receptor (ER) +/HER2+; 57.1% for patients with ER+/HER2-; 65.6% for patients with ER-/HER2+; and 69.2% for ER-/HER2- patients (p < 0.001). Factors associated with RT use included ER-/HER2- status, 70–74 years of age, and high grade disease, while adjuvant RT was associated with improve BCSS in ER+/HER2- and ER-/HER2- patients. Conclusions Patients 70–74 years old and those with ER-/HER2- are more likely to receive adjuvant RT. Moreover, adjuvant RT is associated with improvements in BCSS in ER+/HER2- and ER-/HER2- patients. Given possible poor compliance with hormonal therapy, the omission of RT in ER + patients, without consideration of HER2 status, should be undertaken with care.

Original languageEnglish (US)
Pages (from-to)34-41
Number of pages8
JournalBreast
Volume35
DOIs
StatePublished - Oct 1 2017

Fingerprint

Estrogen Receptors
Radiotherapy
Breast Neoplasms
Neoplasms
Survival
human ERBB2 protein
Background Radiation
Tumor Biomarkers
Epidemiology
Breast
Biomarkers
Logistic Models
Regression Analysis
Databases

Keywords

  • Breast cancer
  • Radiation therapy utilization
  • Tumor biomarkers

ASJC Scopus subject areas

  • Surgery

Cite this

Radiation therapy utilization and outcomes for older women with breast cancer : Impact of molecular subtype and tumor grade. / Haque, Waqar; Kee Yuan, Denley Ming; Verma, Vivek; Butler, E. Brian; Teh, Bin S.; Wiederhold, Lee; Hatch, Sandra.

In: Breast, Vol. 35, 01.10.2017, p. 34-41.

Research output: Contribution to journalArticle

Haque, Waqar ; Kee Yuan, Denley Ming ; Verma, Vivek ; Butler, E. Brian ; Teh, Bin S. ; Wiederhold, Lee ; Hatch, Sandra. / Radiation therapy utilization and outcomes for older women with breast cancer : Impact of molecular subtype and tumor grade. In: Breast. 2017 ; Vol. 35. pp. 34-41.
@article{0f2b779ddd4f4868a9a6b2ac097d6bbe,
title = "Radiation therapy utilization and outcomes for older women with breast cancer: Impact of molecular subtype and tumor grade",
abstract = "Background Radiation therapy (RT) utilization for elderly women with respect to human epidermal growth factor receptor 2 (HER2) receptor status has not been evaluated. Our purpose was to determine differences in RT utilization and breast cancer specific survival (BCSS) for elderly breast cancer patients with distinct molecular biomarkers. Methods The Surveillance, Epidemiology, and End Results database was queried for women ≥70 years of age diagnosed with T1N0M0 breast cancer between 2010 and 2013 receiving breast conservation. Chi-squared analysis was performed to determine the difference in RT utilization between groups. Multivariable logistic regression analysis was performed to determine predictors for RT use. Kaplan-Meier curves were created and the log-rank test done to compare differences in breast cancer specific survival (BCSS) between groups. Results A total of 12,312 patients met the inclusion criteria. Receipt of RT for patients with distinct tumor biomarkers was as follows: 55.7{\%} for patients with Estrogen Receptor (ER) +/HER2+; 57.1{\%} for patients with ER+/HER2-; 65.6{\%} for patients with ER-/HER2+; and 69.2{\%} for ER-/HER2- patients (p < 0.001). Factors associated with RT use included ER-/HER2- status, 70–74 years of age, and high grade disease, while adjuvant RT was associated with improve BCSS in ER+/HER2- and ER-/HER2- patients. Conclusions Patients 70–74 years old and those with ER-/HER2- are more likely to receive adjuvant RT. Moreover, adjuvant RT is associated with improvements in BCSS in ER+/HER2- and ER-/HER2- patients. Given possible poor compliance with hormonal therapy, the omission of RT in ER + patients, without consideration of HER2 status, should be undertaken with care.",
keywords = "Breast cancer, Radiation therapy utilization, Tumor biomarkers",
author = "Waqar Haque and {Kee Yuan}, {Denley Ming} and Vivek Verma and Butler, {E. Brian} and Teh, {Bin S.} and Lee Wiederhold and Sandra Hatch",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.breast.2017.06.011",
language = "English (US)",
volume = "35",
pages = "34--41",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Radiation therapy utilization and outcomes for older women with breast cancer

T2 - Impact of molecular subtype and tumor grade

AU - Haque, Waqar

AU - Kee Yuan, Denley Ming

AU - Verma, Vivek

AU - Butler, E. Brian

AU - Teh, Bin S.

AU - Wiederhold, Lee

AU - Hatch, Sandra

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background Radiation therapy (RT) utilization for elderly women with respect to human epidermal growth factor receptor 2 (HER2) receptor status has not been evaluated. Our purpose was to determine differences in RT utilization and breast cancer specific survival (BCSS) for elderly breast cancer patients with distinct molecular biomarkers. Methods The Surveillance, Epidemiology, and End Results database was queried for women ≥70 years of age diagnosed with T1N0M0 breast cancer between 2010 and 2013 receiving breast conservation. Chi-squared analysis was performed to determine the difference in RT utilization between groups. Multivariable logistic regression analysis was performed to determine predictors for RT use. Kaplan-Meier curves were created and the log-rank test done to compare differences in breast cancer specific survival (BCSS) between groups. Results A total of 12,312 patients met the inclusion criteria. Receipt of RT for patients with distinct tumor biomarkers was as follows: 55.7% for patients with Estrogen Receptor (ER) +/HER2+; 57.1% for patients with ER+/HER2-; 65.6% for patients with ER-/HER2+; and 69.2% for ER-/HER2- patients (p < 0.001). Factors associated with RT use included ER-/HER2- status, 70–74 years of age, and high grade disease, while adjuvant RT was associated with improve BCSS in ER+/HER2- and ER-/HER2- patients. Conclusions Patients 70–74 years old and those with ER-/HER2- are more likely to receive adjuvant RT. Moreover, adjuvant RT is associated with improvements in BCSS in ER+/HER2- and ER-/HER2- patients. Given possible poor compliance with hormonal therapy, the omission of RT in ER + patients, without consideration of HER2 status, should be undertaken with care.

AB - Background Radiation therapy (RT) utilization for elderly women with respect to human epidermal growth factor receptor 2 (HER2) receptor status has not been evaluated. Our purpose was to determine differences in RT utilization and breast cancer specific survival (BCSS) for elderly breast cancer patients with distinct molecular biomarkers. Methods The Surveillance, Epidemiology, and End Results database was queried for women ≥70 years of age diagnosed with T1N0M0 breast cancer between 2010 and 2013 receiving breast conservation. Chi-squared analysis was performed to determine the difference in RT utilization between groups. Multivariable logistic regression analysis was performed to determine predictors for RT use. Kaplan-Meier curves were created and the log-rank test done to compare differences in breast cancer specific survival (BCSS) between groups. Results A total of 12,312 patients met the inclusion criteria. Receipt of RT for patients with distinct tumor biomarkers was as follows: 55.7% for patients with Estrogen Receptor (ER) +/HER2+; 57.1% for patients with ER+/HER2-; 65.6% for patients with ER-/HER2+; and 69.2% for ER-/HER2- patients (p < 0.001). Factors associated with RT use included ER-/HER2- status, 70–74 years of age, and high grade disease, while adjuvant RT was associated with improve BCSS in ER+/HER2- and ER-/HER2- patients. Conclusions Patients 70–74 years old and those with ER-/HER2- are more likely to receive adjuvant RT. Moreover, adjuvant RT is associated with improvements in BCSS in ER+/HER2- and ER-/HER2- patients. Given possible poor compliance with hormonal therapy, the omission of RT in ER + patients, without consideration of HER2 status, should be undertaken with care.

KW - Breast cancer

KW - Radiation therapy utilization

KW - Tumor biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85021097931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021097931&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2017.06.011

DO - 10.1016/j.breast.2017.06.011

M3 - Article

VL - 35

SP - 34

EP - 41

JO - Breast

JF - Breast

SN - 0960-9776

ER -